Oral semaglutide
Aliases: NN9536 · Rybelsus
Oral semaglutide is a oral peptide/small molecule peptide targeting GLP-1R, developed by Novo Nordisk for multiple indications. As of Aug 15, 2024, its highest verified stage is Approved.
Approved· verified Aug 15, 2024
Identity
- Generic name
- semaglutide
- Brand names
- Rybelsus
- Development codes
- NN9536
- Sponsor / originator
- Novo Nordisk
- Targets
- GLP-1R
- Route / formulation
- Oral tablet
Development timeline
- Approved· Type 2 diabetes· United States
As of Aug 15, 2024 · Confidence: high
Source: FDA approves Wegovy (semaglutide) for chronic weight managementFDA approved Rybelsus as first oral GLP-1 receptor agonist for type 2 diabetes.
Trials
View all →No records found.
Regulatory approvals
| Jurisdiction | Brand | Indication | Date |
|---|---|---|---|
| United States | Rybelsus | Type 2 diabetes | Sep 20, 2019 |
Deals
View all →Sources
- regulatoryprimary record
FDA approves Wegovy (semaglutide) for chronic weight management
U.S. Food and Drug Administration · FDA News Release · Jun 4, 2021